Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050830 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
NCT00050830 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 163 participants.
The verdict
NCT00050830, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
Study Summary
The purpose of study to determine the activity of CI 1033 against tumors in patients with advanced or metastatic NSCLC who have failed prior platinum-based combination chemotherapy. Another objective is to determine the safety of CI 1033.
Interventions
- DRUG CI 1033
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2003-01 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050830
The ClinicalTrials.gov registry entry for NCT00050830 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CI 1033 is the first listed.
NCT00050830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050830 about?
NCT00050830 is a clinical study titled "A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer". The purpose of study to determine the activity of CI 1033 against tumors in patients with advanced or metastatic NSCLC who have failed prior platinum-based combination chemotherapy. Another objective is to determine the safety of CI 1033.
What is the current status of trial NCT00050830?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2003-01. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00050830?
The interventions under investigation include: CI 1033 (DRUG).
Who is sponsoring clinical trial NCT00050830?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.